Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Repros Therapeutics Inc.

www.reprosrx.com

Latest From Repros Therapeutics Inc.

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End

Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.

Europe Approvals

Takeda Paves The Way For Myovant With Phase III Fibroid Success

Takeda has reported the first in a wave of Phase III trials to support the potential uterine fibroid therapy relugolix. The news is good for licensee Myovant, which earlier this year started two larger Phase III studies of the product.

Clinical Trials Companies

Execs On The Move, March 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says

US agency's decision not to hold a February advisory committee review of tardive dyskinesia treatment viewed positively by Neurocrine, which emphasized quality of its communications with the review division and the drug's breakthrough therapy status.

Regulation Advisory Committees
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Metabolic Disorders
  • Alias(es)
  • Zonagen Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Repros Therapeutics Inc.
  • Senior Management
  • Larry Dillaha, Pres. & CEO
    Katherine A Anderson, CFO
    Ronald Wiehle, PhD, VP, R&D
    Joachim F Wernicke, MD, PhD, CMO
  • Contact Info
  • Repros Therapeutics Inc.
    Phone: (281) 719-3400
    2408 Timberloch Pl.
    Ste. B-1
    The Woodlands, TX 77380
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register